Correction to: Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach—an Indian experience

Mihika B. Dave¹ · Alpa J. Dherai¹ · Devendra C. Desai² · Diane R. Mould³ · Tester F. Ashavaid¹

Published online: 4 September 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: European Journal of Clinical Pharmacology
<https://doi.org/10.1007/s00228-020-02975-0>

The correct layout of Table 1 is presented in this paper.
The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s00228-020-02975-0>

✉ Alpa J. Dherai
dr_alpa.dherai@hindujahospital.com; alpadherai@gmail.com

¹ Department of Biochemistry, P. D. Hinduja Hospital & MRC, Veer Savarkar Marg, Mahim, Mumbai 400016, India

² Department of Gastroenterology, P. D. Hinduja Hospital & MRC, Veer Savarkar Marg, Mahim, Mumbai 400016, India

³ Projections Research Inc., Phoenixville, PA, USA

Table 1 Patients managed on iDose assisted IFX dosing regimen

Pt Id	Age/ Sex	Year of diag- nosis	Azathio- prine (mg/day)	Duration of IFX therapy (months)	Initial management with IFX		iDose driven IFX regimen	
					Dose	Outcome	Dose	Outcome
Ulcerative colitis								
SM	11 y/F	2016	12.5	24	6.5 mg/kg q4w	Therapeutic IFX concentration	6.5 mg/kg q7w	Clinical remission & Cost reduction
SS	27y/M	2015	-	18	5mg/kg induction dose	Poor response	5 mg/kg q8w	Clinical remission & Cost reduction
JM	40 y/M	2011	50	4	5 mg/kg q8w induction dose	No response	5mg/kg q6w	Clinical improvement
Crohn's disease								
ST	46 y/M	1991	50	96	5 mg/kg q8w changed to q4w	Active disease. Improved with q4w IFX	5mg/kg q7w	Clinical remission & Cost reduction
RM	53 y/M	2001	75	36	5mg/kg q8w changed to 10mg/kg q8w	Sub therapeutic IFX concentration	10 mg/kg q4w	Clinical remission
RJ	14 y/F	2015	37.5	10	5mg/kg q8w	Poor response	5mg/kg q6w	Clinical remission
DN	17 y/M	2018	-	18	5 mg/kg q8w	Initiated on IFX monitoring & iDose assisted dosing	5mg/kg q8w	Clinical remission
TD*	19 y/M	2016	100	6	5mg/kg q8w induction dose	Clinical improvement but sub-therapeutic IFX concentration	5mg/kg q4w	Clinical remission
PJ**	53 y/F	2015	-	36	5 mg/kg q8w	Clinical and endoscopic remission but sub-therapeutic IFX concentration	5mg/kg q6w	Therapeutic IFX concentration
KB	28 y/M	2012	-	13	5 mg/kg q8w	Active disease	5mg/kg q6w	Clinical improvement
VM	29 y/M	2014	50	11	5 mg/kg q8w	Active disease but sub-therapeutic IFX concentration	5mg/kg q6w	IFX stopped due to ADA formation

*patient TD was started on adalimumab in 2016 but later developed antibodies and hence was initiated on vedolizumab. After 10 doses of vedolizumab patient was shifted to Infliximab. Steroids were administered in addition to concomitant azathioprine therapy.

**patient PJ was on concomitant methotrexate therapy which was stopped after she achieved clinical remission

-: No concomitant therapy